# Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults

> **NCT07703956** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Vigonvita Life Sciences** · enrollment: 500 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** VV119 2mg
- **DRUG:** VV119 4mg
- **DRUG:** VV119 6mg
- **DRUG:** Aripiprazole tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07703956
- **Lead sponsor:** Vigonvita Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703956, "Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07703956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*